H.R. 7667
IntroducedFood and Drug Amendments of 2022
Latest Action
Received in the Senate.
6/9/2022 • Senate
Summary
Food and Drug Amendments of 2022
This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.
Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.
In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.
Passed House • 6/8/2022
Topics & Subjects
CBO Cost Estimates (1)
Related Federal Spending
Sponsor & Cosponsors (4)
Party Breakdown
Sponsor
Cosponsors (3)
Bill Journey
Originated in the House
Introduced
May 6, 2022
Committee Review
May 11, 2022
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .
Floor Debate
June 7, 2022
Passed Chamber
June 8, 2022
Other Chamber
June 9, 2022
President
Enacted into Law
Text Versions (4)
Committee Reports (1)
Related Bills (20)
H.R. 2565
FDA Modernization Act of 2021
H.R. 6888
Helping Experts Accelerate Rare Treatments Act of 2022
H.R. 6980
To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.
H.R. 7006
INSPECTIONS Act
H.R. 7032
Increasing Transparency in Generic Drug Applications Act of 2022
H.R. 7035
Biologics Market Transparency Act of 2022
H.R. 7084
PATCH Act of 2022
H.R. 7649
To direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.
H.R. 7658
To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
S. 2952
FDA Modernization Act of 2021
S. 3983
PATCH Act
S. 4152
A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
S. 3478
GAIN TOOLS Act of 2022
H.R. 6988
Drug Manufacturing Innovation Act of 2022
S. 4351
Enhanced Access to Affordable Medicines Act of 2022
S. 4302
Biologics Market Transparency Act of 2022
S. 4333
CLEAR Act
S. 4338
Increasing Transparency in Generic Drug Applications Act
S. 4535
FDASRA Act of 2022
H.R. 9297
Pre-Approval Information Exchange Act of 2022